Adverse events among chronic myelogenous leukemia patients treated with tyrosine kinase inhibitors: a real-world analysis of health plan enrollees

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA A Cancer J Clin. 2019;69:7–34.
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Larson RA, Guilhot F, IRIS Investigators, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376:917–927.
   PubMed Web of Science ®Google Scholar
• Steegmann JL, Baccarani M, Breccia M, et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia. 2016;30:1648–1671.
   PubMed Web of Science ®Google Scholar
• Efficace F, Cardoni A, Cottone F, et al. Tyrosine-kinase inhibitors and patient-reported outcomes in chronic myeloid leukemia: a systematic review. Leuk Res. 2013;37:206–213.
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34:966–984.
   PubMed Web of Science ®Google Scholar
• Darkow T, Henk HJ, Thomas SK, et al. Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. Pharmacoeconomics. 2007;25:481–496.
   PubMed Web of Science ®Google Scholar
• Henk HJ, Woloj M, Shapiro M, et al. Real-world analysis of tyrosine kinase inhibitor treatment patterns among patients with chronic myeloid leukemia in the United States. Clin Ther. 2015;37:124–133.
   PubMed Web of Science ®Google Scholar
• Wilkes JJ, Lyman GH, Doody DR, et al. Health care cost associated with contemporary chronic myelogenous leukemia therapy compared with that of other hematologic malignancies. JCO Oncol Pract. 2020:OP2000143. doi:10.1200/OP.20.00143.
   PubMedGoogle Scholar
• Chow EJ, Cushing-Haugen KL, Cheng GS, et al. Morbidity and mortality differences between hematopoietic cell transplantation survivors and other cancer survivors. J Clin Oncol. 2017;35:306–313.
   PubMed Web of Science ®Google Scholar
• Prentice RL, Williams BJ, Peterson AV. On the regression-analysis of multivariate failure time data. Biometrika. 1981;68:373–379.
   Web of Science ®Google Scholar
• Hess KR. Graphical methods for assessing violations of the proportional hazards assumption in Cox regression. Stat Med. 1995;14:1707–1723.
   PubMed Web of Science ®Google Scholar
• Sasaki K, Kantarjian HM, Jain P, et al. Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors. Cancer. 2016;122:238–248.
   PubMed Web of Science ®Google Scholar
• Menzin J, Lang K, Earle CC, et al. Treatment patterns, outcomes and costs among elderly patients with chronic myeloid leukaemia: a population-based analysis. Drugs Aging. 2004;21:737–746.
   PubMed Web of Science ®Google Scholar
• Bower H, Bjorkholm M, Dickman PW, et al. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016;34:2851–2857.
   PubMed Web of Science ®Google Scholar
• Hoffmann VS, Baccarani M, Hasford J, et al. Treatment and outcome of 2904 CML patients from the EUTOS population-based registry. Leukemia. 2017;31:593–601.
   PubMed Web of Science ®Google Scholar
• Kizaki M, Takahashi N, Iriyama N, et al.; the New TARGET investigators. Efficacy and safety of tyrosine kinase inhibitors for newly diagnosed chronic-phase chronic myeloid leukemia over a 5-year period: results from the Japanese registry obtained by the New TARGET system. Int J Hematol. 2019;109:426–439.
   PubMed Web of Science ®Google Scholar
• Gambacorti-Passerini C, Antolini L, Mahon FX, et al. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst. 2011;103:553–561.
   PubMed Web of Science ®Google Scholar
• Radivoyevitch T, Weaver D, Hobbs B, et al. Do persons with chronic myeloid leukaemia have normal or near normal survival? Leukemia. 2020;34:333–335.
   PubMed Web of Science ®Google Scholar
• Efficace F, Baccarani M, Breccia M, et al.; for GIMEMA. Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. Blood. 2011;118:4554–4560.
   PubMed Web of Science ®Google Scholar
• Phillips KM, Pinilla-Ibarz J, Sotomayor E, et al. Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison. Support Care Cancer. 2013;21:1097–1103.
   PubMed Web of Science ®Google Scholar
• Williams LA, Garcia Gonzalez AG, Ault P, et al. Measuring the symptom burden associated with the treatment of chronic myeloid leukemia. Blood. 2013;122:641–647.
   PubMed Web of Science ®Google Scholar
• Zulbaran-Rojas A, Lin HK, Shi Q, et al. A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors. Cancer Med. 2018;7:5457–5469.
   PubMed Web of Science ®Google Scholar
• Moslehi JJ. Cardiovascular toxic effects of targeted cancer therapies. N Engl J Med. 2016;375:1457–1467.
   PubMed Web of Science ®Google Scholar
• Haguet H, Douxfils J, Mullier F, Chatelain C, et al. Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis. Expert Opin Drug Saf. 2017;16:5–12.
   PubMed Web of Science ®Google Scholar
• Perry AM, Brunner AM, Zou T, et al. Association between insurance status at diagnosis and overall survival in chronic myeloid leukemia: a population-based study. Cancer. 2017;123:2561–2569.
   PubMed Web of Science ®Google Scholar
• Thanarajasingam G, Minasian LM, Baron F, et al. Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies. Lancet Haematol. 2018;5:e563–e598.
   PubMed Web of Science ®Google Scholar
• Laviana AA, Luckenbaugh AN, Resnick MJ. Trends in the cost of cancer care: beyond drugs. J Clin Oncol. 2020;38:316–322.
   PubMed Web of Science ®Google Scholar
• Huntington SF, Davidoff AJ, Gross CP. Precision medicine in oncology II: economics of targeted agents and immuno-oncology drugs. J Clin Oncol. 2020;38:351–358.
   PubMed Web of Science ®Google Scholar
• Dulucq S, Astrugue C, Etienne G, et al. Risk of molecular recurrence after tyrosine kinase inhibitor discontinuation in chronic myeloid leukaemia patients: a systematic review of literature with a meta-analysis of studies over the last ten years. Br J Haematol. 2020;189:452–468.
   PubMed Web of Science ®Google Scholar